Speaker
Description
Pulmonary exacerbations in cystic fibrosis (CF) patients have significant impacts on morbidity, mortality, and quality of life. This study aims to identify risk factors for exacerbations, evaluate the effects of new CFTR modulator therapy, and analyze factors influencing patient response to the therapy. This retrospective, single-center observational study involved CF patients treated with Ivacaftor (n=12) and untreated eligible patients (n=8). The impact of Ivacaftor on severe exacerbations and exacerbation incidence was analyzed using logistic regression and count models. The Zero-Inflated Model was used to account for excess zeros in the count data. Among patients treated with Ivacaftor, one experienced a severe exacerbation (9.1%), while none occurred in the untreated group. Logistic regression indicated that Ivacaftor treatment did not significantly affect severe exacerbation risk (p=0.621). The incidence rate ratio for exacerbations in treated versus untreated patients was 0.91 (p=0.897), suggesting no significant difference. Various predictors were analyzed, including genotypes, diagnosis history, treatment methods, and patient characteristics. Some predictors had significant effects on exacerbation rates, while others showed no significant associations. This study investigated the effects of Ivacaftor treatment on pulmonary exacerbations in CF patients. While some predictors showed associations with exacerbation rates, the overall impact of Ivacaftor treatment and other factors on exacerbation risk varied. These findings contribute to understanding the complex relationship between CFTR modulator therapy and exacerbation risk, helping guide personalized treatment approaches for CF patients.
